Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 8 | 11 | 10 | 10 | 9 | 2 | - |
| Operating profit | $m | -9 | - | |||||
| Net profit | $m | -5 | -9 | -10 | -11 | -12 | -10 | - |
| EPS reported | $ | -91.15 | - | |||||
| Operating cashflow per share | $ | -36.86 | - | |||||
| Capex per share | $ | 0.00 | - | |||||
| FCF per share | $ | -36.86 | - | |||||
| Free cash flow | $m | -4 | - | |||||
| Net debt | $m | -7 | - | |||||
| Book value equity | $m | 3 | - | |||||
| Book value per share | $ | 26.84 | - | |||||
| Number of shares | m | 0.12 | - | |||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.39 | - | |||||
| P/S LTM | x | 0.62 | - | |||||
| P/FCF LTM | x | -0.28 | - | |||||
| EV/EBITDA LTM | x | 0.62 | - | |||||
| EV/Sales LTM | x | -2.81 | - | |||||
| Earnings Yield LTM | % | -876.42% | - | |||||
| FCF Yield | % | -354.42% | - | |||||
| Quality | ||||||||
| ROE | % | -339.60% | - | |||||
| ROIC | % | -267.44% | - | |||||
| Operating margin | % | -465.42% | - | |||||
| Gross margin | % | 1.25% | - | |||||
| FCF/Sales | % | -219.86% | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -79.24% | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | - | |||||
| Dividend Growth | % | 0.00% | - | |||||
| Payout Ratio | % | 0.00% | - | |||||
| FCF/Debt | x | -15.78 | - | |||||
| Net Debt/EBITDA | x | 0.76 | - | |||||
| EBIT/Net interest | x | -4,606.42 | - | |||||
| Net debt/market cap | % | -575.02% | - | |||||
| Net debt/Equity | x | -2.23 | - | |||||
| Gross debt/equity | x | 0.09 | - | |||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free